Cantor Fitzgerald Reiterates Overweight Rating on Solid Biosciences (SLDB)

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating and $16.00 price target on Solid Biosciences (NASDAQ: SLDB).

The analyst commented, “SRPT noted that 30-40% of patients have experienced liver enzyme elevations with ELEVIDYS treatment. While SLDB data is much earlier, the company has looked at key biomarkers of liver injury like GGT (which look flat), as well as biomarkers that one can look at both to look at liver health and muscle integrity (like AST, ALT, CK and LDH), all of which have improvement. SLDB's construct in general is intended to target the cardiac and skeletal muscles, while de-targeting the liver (due to capsid that has RGD peptides; also helps w/ efficacy).”

For an analyst ratings summary and ratings history on Solid Biosciences click here. For more ratings news on Solid Biosciences click here.

Shares of Solid Biosciences closed at $6.39 yesterday.

You May Also Be Interested In

• Hyperion DeFi, Inc. (HYPD) PT Raised to $7.10 at Cantor Fitzgerald
• Anthropic CFO holding pre-IPO, valuation not discussed - report
• Foot traffic at Taco Bell for week of August 3 down 8%, compared to a near 20% decline in mid-July - Placer.AIdata